Caribou Biosciences, Inc.

Caribou Biosciences, Inc. reported a net loss of $148.1 million for the fiscal year ended December 31, 2025, a slight improvement from a net loss of $149.1 million in the prior year. Total operating expenses were $159.5 million, driven primarily by research and development costs of $109.4 million and general and administrative expenses of $37.9 million. The company generated $11.2 million in licensing and collaboration revenue. As of December 31, 2025, Caribou had cash, cash equivalents, and marketable securities totaling $142.8 million, which it expects to fund operations for at least the next 12 months. The company's strategic focus remains on advancing its two clinical-stage allogeneic CAR-T cell therapy product candidates, vispa-cel and CB-011, following a pipeline prioritization and workforce reduction announced in April 2025.

Key Takeaways